Management Forum courses now available at IPI Academy - visit IPI for an updated experience and a broader selection of courses and subjects

Common Technical Document Training Course

A comprehensive review of the regulations and technical requirements for chemistry, manufacturing and control (CMC) management of your application.

1-2 Dec 2021

& 1-2 Feb 2022 , 5-6 May 2022 , 28-29 Nov 2022

Book now

Details

Course Overview

This interactive two-day course will provide you with a clear and comprehensive understanding of the regulatory and technical requirements for CMC management of your full and generic application in major markets of the EU and USA. Furthermore, the course examines the requirements for global roll-out of the dossier to ROW regions including LATAM, ASEAN, MENA and CIS territories.

You will increase your ability to manage all aspects of development of the CMC applications after two days of intensive lectures, group work and discussion sessions, covering everything you need to know about compiling the chemistry and pharmacy section of your generic dossier.

Skills you will gain include:

  • Effective compilation of the Common Technical Document (CTD) and critical review of documentation
  • Quality by design (QbD), critical attributes and developing new product using the CQA pyramid model
  • Compiling and submitting Module 3 (CTD) of your registration dossier
  • Identifying the extent of content expected by EU and US regulators
  • Achieving the quickest turnaround of your submission
  • Managing the pharmaceutical and quality aspects of your developments and registration dossier in Europe and the US
  • Ensuring right-first-time development
  • Meeting the legal framework and guidelines for the CMC/quality part of the dossier and links to GMP

Who should attend

  • Senior analytical chemists
  • Formulation chemists
  • Technical services chemists
  • Registration staff (all levels)
  • Quality managers
  • Quality control directors
  • R&D project managers

Programme

What is the CTD?

  • The road map to Module 3 and understanding ICH
  • Assessing the impact of harmonisation – ICH guidelines

Preparing the drug substance section of the application – US and EU

  • Analysing the needs for the section
  • How to submit information – drug master files, certificates of suitability (CEP) and other methods
  • European submissions, CEP and active substance master file (ASMF) requirements
  • Detailed information requirements for the section
  • Q11 explained – EU and US expectations of failure mode and effects analysis (FMEA)
  • Development expectations and scale-up requirements
  • Specific examples of EU/US format and guidance

GMP for active substances

  • Examining GMP requirements and EU and US expectations, inspection timing and interactions and contractual obligations

Case study: Essential information from API suppliers

  • Identify and understand the essential data requirements from API suppliers for submission of generic applications

Examining the content of the sections concerning the drug product composition and development of the drug product

  • Defining the formulation
  • Identifying the data needs for the pharmaceutical development section, explaining QbD and FMEA requirements
  • Multiple examples of development report content – practical for table of contents and creation of QbD pyramid

Writing the section on manufacture of the drug product and process validation

  • Examining the content of the section: how much information to provide
  • Defining the difference between process development and validation and looking at validation expectations in today’s environment

Writing the sections on excipients and packaging components

  • Control of the excipients/packaging components
  • Examples of data expectations
  • Examining the maintenance of these sections

Writing the sections on control of the finished product and case study

  • Examining the content of the section
  • Control of the drug product
  • Examples of specifications for multiple product types
  • Examples for method summaries

Writing the stability section

  • Examining the content of the section
  • Evaluation of stability data and the impact on shelf life

The function and content of the Quality Overall Summary (QOS)

  • Overview of the current approaches
  • What is the Expert Report: practical involvement of the expert
  • QOS explained and compared with Expert Report
  • Detailed content of the QOS

Examining global roll-out of Module 3

Examining change control – practical tips

Practical exercise in generic development

  • Identifying ten-stage plan for developments

Presenters

Hans van Bruggen (More...) (1-2 Dec 2021)

Hans van Bruggen is CEO of and Senior Regulatory Affairs Scientist at Qdossier. He holds an MSc. in Pharmaceutical Medicine from the University of Surrey (UK) and has worked in the pharmaceutical industry for more than 35 years, primarily at global or European headquarters sites. He has gained a wealth of experience and a comprehensive view on what information is needed to evaluate the benefit/risk ratio of drugs for patients and healthy volunteers. He approaches interdisciplinary and international processes using that scientific background. He applies new technologies and Artificial Intelligence to facilitate the business and let people focus on what they can do best.

Marloes van der Geer (More...) (1-2 Dec 2021)

Marloes van der Geer works as senior regulatory affairs scientist at Qdossier. Marloes holds a master in Life Sciences (Drug Innovation) from the University of Utrecht, the Netherlands. For nine years she held several positions at Hoffmann-la Roche in Switzerland, including the role of regulatory intelligence manager and regulatory policy lead for the EMEA region. Marloes has been actively involved in several industry associations like EFPIA and IFPMA. Also, she contributed to the ongoing IMI PREFER project in Europe, focused on the generation and use of patient preference data. In 2019, Marloes joined Qdossier. Marloes’ areas of expertise are: eCTD, lean authoring, publishing, biopharmaceuticals (incl. biosimilars), clinical development, regulatory convergence & harmonization and facilitated registration pathways (incl. orphan drugs), local RA activities (e.g. product information management).

Maikel Bouman (More...) (1-2 Dec 2021)

Maikel Bouman works as a Senior Regulatory Operations Manager at Qdossier and in his role he has a strong focus on managing Regulatory Operations, coordination, and development of staff; planning and coordination of projects, including regulatory filings of dossiers across various regions and development and maintenance of technical solutions supporting Regulatory Operations. Maikel has a broad subject matter expertise on the quality control of data, document publishing, planning/coordination, management, preparation/creation and dispatch of different types of electronic submission formats to various regulatory authorities such as the United States, Canada, Europe, Australia and Switzerland.



Book now

Book now

1-2 Dec 2021
Live webinar
1-2 Dec 2021
Live webinar
GBP 1,299 1,099
EUR 1,859 1,579
USD 2,098 1,786
Until 1 Nov*
Enrol now
to attend
Live webinar
1-2 Feb 2022
Face-to-face, (venue not yet confirmed)
1-2 Feb 2022
Face-to-face
(venue not yet confirmed)
GBP 1,499 1,299
EUR 2,099 1,819
USD 2,338 2,026
Until 28 Dec*
Enrol now
to attend
Face-to-face
(venue not yet confirmed)
  • 2 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy
5-6 May 2022
Live webinar
5-6 May 2022
Live webinar
GBP 1,299 1,099
EUR 1,859 1,579
USD 2,098 1,786
Until 31 Mar 22*
Enrol now
to attend
Live webinar
28-29 Nov 2022
Live webinar
28-29 Nov 2022
Live webinar
GBP 1,299 1,099
EUR 1,859 1,579
USD 2,098 1,786
Until 24 Oct 22*
Enrol now
to attend
Live webinar

Learn more about our face-to-face and webinar training formats.

* Note the early booking discount cannot be combined with any other offers or promotional code

Continuing professional development

This course qualifies for 12 hours for your CPD records.
More about CPD

Customised in-house training

We can customise this course to meet the requirements of your organisation and deliver it at your location and/or online.

Contact us

You may also be interested in

Previous customers include...

  • Actavis UK Ltd, a subsidiary of Accord Healthcare Ltd
  • Actelion Pharmaceutical Ltd
  • Advanced Accelerator Applications
  • ALK-Abelló A/S
  • Ares Trading S.A.
  • argenx bvba
  • Aurora Nordic Cannabis A/S
  • Bayer AG
  • Beaphar B.V.
  • Biovet JSC
  • DNDi
  • dne pharma AS
  • Elanco UK AH Limited
  • Ferring Pharmaceuticals Inc
  • Gedeon Richter Ltd
  • Genethics Regulatory Services Ltd
  • Genzyme Ireland Ltd
  • GW Pharmaceuticals
  • M & A Pharmachem Ltd
  • Masters Speciality Pharma
  • Niacet b.v.
  • Orphan Europe
  • PhaRA
  • Pharmavize (Ardena)
  • Pharmex Advanced Laboratories, S.L.
  • Recipharm AB
  • Recipharm Pharmaceutical Development AB
  • Teva UK Ltd
  • Wockhardt (UK) Ltd
  • Xellia Ltd

An excellent 2 days - required lots of concentration but worth it. It was very engaging and encouraged me to continue learning and improving.

Jane Kean, Regulatory Associate, Elanco UK AH Limited, Jul 21

Excellent presentation by a first-class speaker who has a wealth of knowledge. I particularly liked the interactive exercises.

Wil Pantin, New Product Introduction Manager, M & A Pharmachem Ltd, Dec 19

Great speaker, capable of transmitting his knowledge in an enjoyable and interactive way.

Rocio Arias, Regulatory Affairs Technician , Pharmex Advanced Laboratories, S.L., Dec 19

It was one of the best workshops I have attended: content was according to expectations, all questions were answered, presenter was passionate and kept the energy high during the presentations.

Iris Vanwelkenhuysen, CMC Dossier Leader, Galapagos, Dec 19

The speaker is really an expert on the CTD requirements and teaches the mindset required to make up a good dossier. I learned a lot from this course.

Wendy Masman, Regulatory Affairs Officer, Beaphar B.V., Dec 19

The speaker was not only very professional, but also kept the mood light and fun. I enjoyed his way of putting things into perspective and making me think in a whole other way from what I am used to. The exercises ... helped with better understanding the material. Overall, a really good course and a great speaker giving both theoretical and practical tools to understand the CTD and importance of the Module 3.

Joanna Sadiq, Regulatory Manager, LINK Medical ApS, Jul 19

Excellent!

Vilma Smith, Senior Manager, Global Regulatory CMC, Bristol Myers Squibb, Jul 19

Good speaker, updated information and good discussions. The group assignments were terrific for learning and understanding.

Hilde Reiersen, Research Scientist, GE Healthcare AS, Jul 19

Excellent speaker! Good interaction! Wonderful course.

Marjana Grønvall, Regulatory affairs professional, ALK-Abelló A/S, Dec 18

Superbly knowledgable speaker and great training style - content was very helpful

Andrew Germain, Associate Director, CMC Regulatory Affairs, GW Pharmaceuticals, Dec 18

Very clean. Very clear speaker. Presentation and content are well adapted.

Sonia Bchir Kassassi , Regulatory Affairs CMC Expert, GUERBET, Jul 18

Very lively presentation, interactivity, exercises to keep the interest.

Natacha Gonzalez, CMC Dossier & Compliance Specialist, Ares Trading S.A., Jul 18

I really enjoyed the presentation, which I found really interesting.

Maria Biri, CMC Dossier Development & Coordination Supervisor, ELPEN Pharmaceutical Co. Inc., Dec 17

Experienced speaker

Julie de Smet, Regulatory Affairs Consultant, PharmaVize NV, Dec 17

Very interactive course. Very interesting.

Fanny Valleix, Head Clinical Research, ImmuPharma , Dec 17